ilyas sahin, MD· @ilyassahinMD · X·· 1 天前评分70
正文 · 原文
Two more #ESMO26 papers in @NEJM today:
In EGFR-mutated, MET-altered NSCLC progressing on osimertinib, adding savolitinib improved PFS (HR 0.55) and OS (HR 0.68) vs platinum-pemetrexed. 12-month OS was 70% vs 53%.
In previously treated KRAS G12C-mutated NSCLC, divarasib improved median PFS (9.8 vs 5.7 months; HR 0.58) and OS (17.7 vs 12.0 months; HR 0.56) vs sotorasib or adagrasib.
109 浏览 · 0 赞 · 0 转发 · 0 回复
来源：ilyas sahin, MD · x.com